Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma (RRMM) from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from KarMMa-3 study of health-related quality of life in patients who received Abecma will be presented at
Abecma (idecabtagene vicleucel) generated $118 million U.S. commercial revenue in 1Q 2023, supporting upper end of U.S. revenue guidance of $470-570 million U.S. FDA accepted supplemental Biologics License Application (sBLA) based on results from the pivotal phase 3 KarMMa-3 study of Abecma;
Late-breaking oral presentation will show early findings from Phase I PLAT-08 study of SC-DARIC33, an investigational, potentially first-in-class CD33-targeting CAR T in pediatric and young adults with relapsed/refractory acute myeloid leukemia (AML) Updates on the Company’s portfolio include
2seventy bio plans to present data at virtual Research and Development deep dive on May 19, 2023 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 1, 2023-- 2seventy bio, Inc. (Nasdaq: TSVT) a leading immuno-oncology cell therapy company, today announced that it has achieved a preclinical $15 million
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 28, 2023-- 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, will announce its first quarter 2023 financial results on Wednesday, May 3, 2023 . 2seventy bio will host a conference call and webcast at 4:30 p.m.
U.S. FDA accepted Bristol Myers Squibb and 2seventy bio’s supplemental Biologics License Application and has assigned a target action date of December 16, 2023 European Medicines Agency has validated Bristol Myers Squibb’s Type II variation application for Abecma Bristol Myers Squibb’s supplemental
Abecma (idecabtagene vicleucel) generated $ 94M U.S. commercial revenue in 4Q 2022, $297M in FY 2022; anticipate $470-$570M U.S. revenue in 2023 Positive data from Phase 3 KarMMa-3 study published in New England Journal of Medicine Ended 2022 with $268M cash, cash equivalents, and marketable
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 8, 2023-- 2seventy bio, Inc. (Nasdaq: TSVT) today announced the appointment of Wei Lin , M.D. to the company’s Board of Directors, effective immediately. “We are thrilled to welcome Dr. Wei Lin to 2seventy’s Board during an exciting time in our Company’s
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 3, 2023-- 2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will present at the 43rd Annual TD Cowen Health Care Conference at the Boston Marriott Copley Place in Boston, MA on March 7, 2023 at 10:30am ET .
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2023-- 2seventy bio, Inc. (“2seventy bio”) (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced today the pricing of a follow on underwritten public
